Spring Bank Pharmaceuticals Partners With Gilead Sciences

July 10, 2017

Spring Bank Pharmaceuticals said early Monday it is collaborating with Gilead Sciences (GILD) in a second clinical trial examining the use of Spring Bank’s immunomodulator, SB9200, with Gilead’s Vemlidy for the treatment of chronic hepatitis B.The phase 2 trial will be funded and implemented by Gilead Sciences.

In May, Spring Bank released top-line results from the initial cohort of the phase 2a segment of the Achieve trial that suggested that a low dose of SB 9200 alone may be able to reduce hepatitis B surface antigen levels in patients with chronic hepatitis B, a critical first step in achieving functional cure. Under the terms of the clinical trial supply and collaboration agreement, Gilead will lead the phase 2 trial with input from Spring Bank.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Bryan Smith

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: